Transforming India into a Global Biopharma Hub
Table of Contents
Relevance:
GS Paper II (Governance & Health Policy)
Important Keywords
For Prelims:
- Biopharma SHAKTI, Union Budget 2026–27, Biologics, Biosimilars, National Biopharma Mission (NBM), Innovate in India (i3), BIRAC, Department of Biotechnology (DBT), CDSCO, NIPERs, Genome India Programme, ZyCoV-D, Production Linked Incentive (PLI) Scheme,
For Mains:
- Global Biopharma Hub, Pharmaceutical Value Chain Upgradation, Health Security, Innovation-driven Growth, Regulatory Credibility, Clinical Trial Ecosystem, Technology Transfer, Bio-entrepreneurship, Import Substitution, Supply Chain Resilience.
Why in News?
The Union Budget 2026–27 has announced Biopharma SHAKTI, a ₹10,000 crore initiative aimed at strengthening India’s biologics and biosimilars ecosystem, signalling a strategic shift from generic drug manufacturing to high-value, innovation-driven biopharmaceuticals.
Background: Why Biopharma Is Strategically Important
Biopharma refers to the development and manufacture of medicines using living biological systems such as human or animal cells, bacteria, fungi and microbes. Unlike traditional chemical drugs, biopharmaceuticals are complex, targeted, and high-value therapies.
Examples include:
- Vaccines
- Monoclonal antibodies
- Biosimilars
- Recombinant insulin
- Gene and cell therapies
- Therapeutic proteins
The global healthcare landscape is witnessing:
- Rising non-communicable diseases (cancer, diabetes, autoimmune disorders)
- Increased reliance on biologics and biosimilars
- Rapid expansion of the $1.1 trillion global pharmaceutical market
This makes biopharma central to health security, economic growth, innovation, and strategic autonomy.
Union Budget 2026–27: Biopharma SHAKTI Initiative
Key Budget Announcements
Biopharma SHAKTI
- Outlay: ₹10,000 crore (5 years)
- Objective: Strengthen end-to-end ecosystem for biologics and biosimilars
- Reduce import dependence and enhance global supply chain integration
Human Resource Development
- Establishment of 3 new NIPERs
- Upgradation of 7 existing NIPERs
- Creation of specialised talent in biopharma R&D, manufacturing and regulation
Clinical Research Expansion
- Development of 1,000+ accredited clinical trial sites
- Enables large-scale, ethical, and globally compliant trials
Regulatory Strengthening
- Capacity enhancement of CDSCO with specialised scientific manpower
- Faster approvals aligned with global regulatory standards
Why This Matters
The Budget integrates manufacturing scale, skilled manpower, clinical research, and regulatory credibility into a single framework. This signals a clear intent to move India:
- From generic drug leadership
- To a high-quality, innovation-driven biopharma powerhouse
It strengthens domestic access to advanced therapies while positioning India as a trusted global supplier.
Government Initiatives to Strengthen India’s Biopharma Sector
National Biopharma Mission (NBM) – “Innovate in India (i3)”
Launched in May 2017, the National Biopharma Mission (NBM) is a flagship initiative aimed at transforming India into a $100-billion global biotech industry and capturing 5% of the global pharmaceutical market.
- Outlay: ₹1,500 crore
- Funding: Co-funded by the World Bank
- Implementing Agency: Biotechnology Industry Research Assistance Council (BIRAC)
- Nodal Ministry: Department of Biotechnology
Focus Areas
- Vaccines (HPV, Dengue)
- Biosimilars (Cancer, Diabetes, Rheumatoid Arthritis)
- Bio-therapeutics
- Diagnostics and medical devices
Key Achievements
- 101 projects supported involving 150+ organisations and 30 MSMEs
- 1,000+ jobs created, including 304 scientists
- Establishment of clinical trial sites with a database of 8 lakh volunteers
- Integration with the Genome India Programme (10,000 genome sequencing)
- Support to development of ZyCoV-D, the world’s first DNA-based COVID-19 vaccine
NBM as a Catalyst of India’s Health Innovation Ecosystem
NBM has played a crucial role in translating scientific research into affordable healthcare solutions, nurturing a new generation of biotech entrepreneurs.
- Voxel Grids Innovations Pvt. Ltd. (Bengaluru)
- Developed India’s first indigenous MRI scanner comparable to global standards
- Funded ₹12.4 crore by BIRAC
- Deployed in cancer hospitals in Mumbai and Assam
- Levim Lifetech Pvt. Ltd. (Chennai)
- Developed India’s first biosimilar of Liraglutide for Type-2 diabetes
- Priced at one-third of imported versions
- 85% clinical trial costs supported under NBM
Additional outcomes:
- ~10,000 biotech start-ups supported since 2014
- 100+ bio-incubation centres established
- 7 Regional Technology Transfer Offices
- 850+ IP filings and 120 technology transfers
- 7,000+ professionals trained, including 45% women
- Voxel Grids Innovations Pvt. Ltd. (Bengaluru)
BIRAC-Led Biotech Innovation Support
Established in 2012, BIRAC acts as the innovation financing and incubation backbone of India’s biotech ecosystem.
Key Schemes
Biotechnology Ignition Grant (BIG):
- Up to ₹50 lakh for early-stage start-ups (1,000+ innovators supported)
SEED Fund:
- ₹30 lakh equity support for proof-of-concept
LEAP Fund:
- ₹100 lakh for commercialisation-ready technologies
जनCARE – Amrit Grand Challenge:
- 89 digital health innovations in AI, ML, telemedicine, blockchain
- Focus on Tier-II, Tier-III cities and rural areas
Manufacturing and Industrial Strengthening Measures
To reduce import dependence and strengthen domestic supply chains, the government has launched:
- Production Linked Incentive (PLI) Scheme for Pharmaceuticals
- Strengthening of Pharmaceutical Industry (SPI) Scheme
- Bulk Drug Parks Scheme
Key Objectives
- Boost manufacturing capacity
- Reduce dependence on imported APIs and intermediates
- Upgrade MSMEs to WHO-GMP standards
- Create common infrastructure in pharma clusters
- Improve export competitiveness and supply chain resilience
Promotion of Research and Innovation in Pharma-MedTech (PRIP)
Launched in 2023 with an outlay of ₹5,000 crore, the PRIP scheme aims to build an innovation-driven Pharma-MedTech ecosystem.
- Supports:
- New drugs and biosimilars
- Precision medicine
- Complex generics
- Advanced medical devices
- Promotes industry–academia collaboration
- Establishes Centres of Excellence at NIPERs
BioE3 Policy and Bio-RIDE Scheme
BioE3 Policy (Approved August 2024)
Biotechnology for Economy, Environment and Employment
Strategic Sectors
- Precision biotherapeutics
- Biobased chemicals and enzymes
- Functional foods and smart proteins
- Climate-resilient agriculture
- Carbon capture and utilisation
- Marine and space biotechnology
Bio-RIDE Scheme (Launched September 2024)
- Outlay: ₹9,197 crore (15th Finance Commission period)
- Merged DBT umbrella schemes
- Added Biomanufacturing and Biofoundry component
Three Pillars
- Biotechnology R&D
- Industrial & Entrepreneurship Development
- Biomanufacturing and Biofoundry
Conclusion
India’s biopharma strategy reflects a deliberate and integrated policy approach—linking research, innovation, manufacturing, entrepreneurship and regulation. As the country’s disease profile shifts toward chronic and non-communicable diseases, access to biologic therapies becomes central to both health outcomes and economic growth.
The Biopharma SHAKTI initiative announced in Union Budget 2026–27, with an outlay of ₹10,000 crore, builds upon this foundation by strengthening workforce capacity, clinical research infrastructure and regulatory efficiency. Together, these initiatives position India to emerge not just as the “pharmacy of the world”, but as a global biopharma innovation and manufacturing hub.
UPSC PYQ
Q. Biotechnological research is promoted through the development of Biotechnology Parks.
Which of the following is/are essential to bring technology to market? (CAPF 2024)
- Development of new product
- Entrepreneurship
- Technology incubation
-
- 1 only
- 1 and 2 only
- 1, 2 and 3
- 2 and 3 only
- Statement 1 – Correct Development of new products is the starting point of technology commercialisation. Without product development, research cannot translate into market outcomes.
- Statement 2 – Correct Entrepreneurship converts technological innovation into viable business ventures. It provides risk-taking ability, business models, and market orientation.
- Statement 3 – Correct Technology incubation bridges the gap between laboratory research and the market by providing infrastructure, mentorship, regulatory support, and seed funding.
CARE MCQ
Q. Consider the following statements regarding the National Biopharma Mission (NBM) – Innovate in India (i3):
- It was launched in 2017 to transform India into a leading global biotech industry.
- It is co-funded by the World Bank and implemented by BIRAC under the Department of Biotechnology.
- It focuses on developing vaccines, biotherapeutics, diagnostics and medical devices.
- 1 and 2 only
- 2 and 3 only
- 1 and 3 only
- 1, 2 and 3
- Statement 1 is correct: The National Biopharma Mission was launched in May 2017 with the objective of transforming India into a leading global biotech industry.
- Statement 2 is correct: The mission is co-funded by the World Bank and implemented by BIRAC under the Department of Biotechnology (DBT).
- Statement 3 is correct: The mission focuses on vaccines, biotherapeutics, diagnostics, and medical devices to address the disease burden and improve affordability and access.
